62nd ASH Annual Meeting and Exposition: 641. CLL: Biology and Pathophysiology, excluding Therapy: Treatment Resistance and Prognosis

Oral and Poster Abstracts
Oral

Adult, Biological, Leukemia, antibodies, Coronaviruses, SARS-CoV-2/COVID-19, CLL, Diseases, Lymphoma (any), Therapies, CAR-Ts, Combinations, checkpoint inhibitors, cellular interactions, Non-Hodgkin Lymphoma, Biological Processes, white blood cells, Technology and Procedures, immune cells, epigenetics, Cell Lineage, immunotherapy, Study Population, Lymphoid Malignancies, Clinically relevant, genetic profiling, genomics, imaging, immune mechanism, flow cytometry, TKI, integrative -omics, NGS, RNA sequencing, pathogenesis, WGS, pathways, signal transduction

Moderators:

Sami Malek, MD, University of Michigan and Paolo Strati, MD, MD Anderson Cancer Center:

Disclosures:

Malek: ABBV: Current equity holder in publicly-traded company; Astra Zeneca: Consultancy; EPZM: Current equity holder in publicly-traded company.

9:30 AM

348

Single-Cell Multi-Omics Reveals Distinct Paths to Survival of Admixed BTK^C481 Mutant Vs. Wild-Type Cells in Clinically Progressing Chronic Lymphocytic Leukemia

Andrew Lipsky, MD¹, Danny Luan, MPH², Shirley Chen, BSc²^*, Ronan Chaligne, PhD³^*, Neville Dusaj, MS⁴^*, Erica B Bhavsar, BS⁵^*, Chelston Ang, MS⁶^*, Anna S Nam, MD⁷, Federico Gaiti, PhD³^*, Paulina Chamely, MSc³^*, Nathaniel D. Omans, MS²^*, Preeti Trisal, MS⁸^*, Anita K Gandhi, PhD⁸, Kyu-Tae Kim, PhD⁹^*, Rafael Schulman, BS¹⁰^*, Joshua S. Schiffman, PhD¹¹^*, Franco Izzo, PhD³^*, Gregory Mullokandov, MD, PhD⁵^*, Chingiz Underbayev, MD, PhD¹², Adrian Wiestner, MD, PhD¹², John N. Allan, MD⁵, Richard R. Furman, MD¹³ and Dan A. Landau, MD, PhD³

¹Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
²Weill Cornell Medical College, New York, NY
³Meyer Cancer Center & Institute of Computational Biomedicine, Weill Cornell Medicine, New York, NY
⁴Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY
⁵Weill Cornell Medicine, New York, NY
⁶University of North Carolina School of Medicine, Chapel Hill, NC
⁷Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, NEW YORK, NY
⁸Bristol Myers Squibb, Summit, NJ
⁹Department of Physiology, Ajou University School of Medicine, Suwon, NY, Korea, Republic of (South)
¹⁰SUNY-Upstate Medical College, New York
¹¹New York Genome Center, New York, NY
¹²Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
¹³Morton Coleman, M.D. Distinguished Professor of Medicine Weill Cornell Medical College, New York, NY

9:45 AM

349

Pre-Existing T Cell Subsets Determine Anti-PD1 Blockade Response in Richter’s Transformation

Prajish Iyer, PhD¹^*, Lu Yang, PhD²^*, Zhi-Zhang Yang, PhD³, Charla R. Secreto⁴^*, Sutapa Sinha, PhD⁴, Neil E. Kay, MD⁴, Stephen M. Ansell, MD, PhD⁵, Lili Wang, MD, PhD⁶, Wei Ding, MD, PhD⁵ and Hyojin Kim, PhD⁵^*

¹Systems Biology Department, City of Hope National Medical Centre, Monrovia, CA
²Department of Systems Biology, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA
³Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN
⁴Division of Hematology, Mayo Clinic, Rochester, MN
⁵Mayo Clinic, Rochester, MN
⁶Department of Systems Biology, Beckman Research Institute, City of Hope, Monrovia, CA

10:00 AM

350

The IGLV3-21^R110 Defines a Subset of Chronic Lymphocytic Leukemia with Intermediate Epigenetic Subtype and Poor Outcome

Ferran Nadeu^1,2^*, Romina Royo³^*, Guillem Clot^1,2^*, Martí Duran-Ferrer¹^*, Alba Navarro, PhD^1,2^*, Silvia Martín^1,2^*, Junyan Lu⁴^*, Thorsten Zenz⁵, Tycho Baumann⁶^*, Pedro Jares^1,2,6,7^*, Xose S Puente, PhD^2,8^*, Jose Ignacio Martin-Subero^1,2,7,9^*, Julio Delgado, MD, PhD^1,2,6^* and Elias Campo, MD PhD^1,2,6,7

¹Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
²Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
³Barcelona Supercomputing Center (BSC), Barcelona, Spain
⁴European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
⁵Medical Oncology and Haematology, University Hospital Zürich, Zürich, Switzerland
⁶Hospital Clínic of Barcelona, Barcelona, Spain
⁷Universitat de Barcelona, Barcelona, Spain
⁸Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, Oviedo, Spain
⁹Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

10:15 AM

351

B-CLL Mediated Resistance to CAR T Cell Therapy Via Insufficient Activation Is CAR-Independent

McKensie Collins, BS, Weimin Kong, Ph.D.^*, Inyoung Jung, BS^*, Stefan M Lundh, BS^* and J. Joseph Melenhorst, PhD

Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

10:30 AM

352

Ibrutinib Off-Target Inhibition Inhibits Antibody-Dependent Cellular Phagocytosis but Not Efferocytosis of CLL Cells

Charles C. Chu, PhD¹, Jonathan J. Pinney, PhD²^*, Sara K. Blick-Nitko, MS³^*, Andrea M. Baran, MS¹^*, Derick R. Peterson, PhD¹^*, Hannah E. Whitehead²^*, Raquel Izumi, PhD⁴, Veerendra Munugalavadla, PhD⁴, Paul M. Barr, MD¹, Karl R. VanDerMeid, BS¹^*, Michael Rusty Elliott, PhD^2,5^* and Clive S. Zent, MD¹

¹Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
²Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY
³Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY
⁴Acerta Pharma, South San Francisco, CA
⁵Center for Cell Clearance and the Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

641.O2.6 641. CLL: Biology and Pathophysiology, excluding Therapy: Treatment Resistance and Prognosis